Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2011 Nov;11(11):1671-6. doi: 10.1586/era.11.163.

Role of bacillus Calmette-Guérin in the treatment of advanced melanoma.

Author information

1
Department of Surgery, Tumor Immunotherapy Program, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. jhstewar@wfubmc.edu

Abstract

Early trials of Bacillus Calmette-Guérin (BCG)-based immunotherapy for melanoma consistently show a trend toward improved clinical outcomes in patients treated with BCG compared with observation alone. As an extension of these findings, investigators have initiated the Malignant Melanoma Active Immunotherapy (MMAIT) trials in patients with stage III (MMAIT-III) and stage IV (MMAIT-IV) disease. The overall survival of the patients receiving BCG plus placebo was much better than expected in both studies, thus suggesting a potential for BCG as an adjuvant after the resection of advanced disease. The work contained herein will explore the clinical rationale for adjuvant BCG in future trials focused on the treatment of patients with advanced malignant melanoma.

PMID:
22050015
DOI:
10.1586/era.11.163
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center